Invivyd, Inc.
IVVDHeld by 9 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying9 funds opened new positions. Next phase3 readout (VYD2311-SD): Aug 2026. Short interest: 11.7% of float.
Held by 9 specialist biotech funds
High ConvergenceHigh short interest · No specialist buying9 funds opened new positions. Next phase3 readout (VYD2311-SD): Aug 2026. Short interest: 11.7% of float.
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatment and prevention of coronavirus disease. Adagio Therapeutics, Inc. has a collaboration agreement with Adimab, LLC for the discovery and optimization of proprietary antibodies; and the Scripps Research Institute to perform research activities to identify vaccine candidates for the prevention, diagnosis or treatment of influenza or beta coronaviruses. The company was incorporated in 2020 and is based in Waltham, Massachusetts.
Be first to know when this name moves
Fund buys and exits, insider activity, and catalyst alerts across 800+ biotechs — free Monday brief.